NEWS

Investment and New Board Leadership Will Support the Path to Commercialization for Investigational Drug, Lasofoxifene  COLUMBUS, OH (May 3, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced Anthony H. Wild, Ph.D., as Chairman of the Board and also a [...]

COLUMBUS, OH (March 31, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, announced today it will deliver an oral presentation related to its investigational drug, lasofoxifene, at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease (WCO-IOF-ESCEO) [...]

Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, announced today that experts in sexual medicine will give two presentations related to its investigational drug, lasofoxifene, at the annual meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH) on [...]

Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced researchers will present a scientific poster about its investigational drug, lasofoxifene, at the upcoming American Society for Bone and Mineral Research Annual Meeting (ASBMR). The meeting takes place in Seattle, [...]

Research on the Company’s Investigational Drug, Lasofoxifene, Takes First Place Among Scientific Posters COLUMBUS, OH (October 7, 2015) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced it received top honors for its research on investigational drug lasofoxifene at [...]

Company to Share Results from Studies of Investigational Drug, Lasofoxifene COLUMBUS, OH (September 16, 2015) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, announced today that experts and researchers will provide three presentations and a poster about its investigational [...]

COLUMBUS, OH — (Marketwired) — 07/23/15 — Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, recently convened the inaugural meeting of its Scientific Advisory Board. The board, which includes leading multidisciplinary experts in selective estrogen receptor [...]

The Sermonix Scientific Advisory Board meets at Inn Walden, Aurora, Ohio June 11th and 12th to discuss lasofoxifene and women’s menopausal health issues. The group, composed of some of the world’s leading experts in selective estrogen receptor modulators, hormone therapy, osteoporosis, VVA and breast cancer will analyze lasofoxifene clinical data. Resubmission and [...]

SAN DIEGO, Feb 03, 2015 (BUSINESS WIRE) — Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral lasofoxifene in the United States and additional territories. Under the terms of the agreement, Ligand has received an undisclosed initial payment, and is entitled to receive […]